Revelation Biosciences director awarded 15,625 shares; vest Jan 2026

Rhea-AI Filing Summary

Revelation Biosciences (REVB) reported an insider equity award. A company director acquired 15,625 shares of Common Stock on 10/29/2025, reported at a $1.28 price per share, as a restricted stock grant under the 2021 Equity Incentive Plan.

The grant vests 100% on January 28, 2026. Following the transaction, the reporting person beneficially owned 15,688 shares, held directly.

Insider Trade Summary

Net Buyer: 15,625 shares

Net Buy 2 txns

Insider CARVER JENNIFER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$1.28	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 15,751 shares (Direct)

Footnotes (1)

1. F1. Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/31/2025 - 12:56 PM Learn about SEC filing dates

FAQ

What did REVB disclose in this Form 4?

A director acquired 15,625 shares of restricted common stock on 10/29/2025, reported at $1.28 per share.

When do the REVB restricted shares vest?

The restricted stock grant vests 100% on January 28, 2026.

How many REVB shares does the insider own after the transaction?

Beneficial ownership after the transaction is 15,688 shares, held directly.

What plan governs the REVB equity grant?

The award is a Restricted Stock Grant under the 2021 Equity Incentive Plan.

What was the reported price for the REVB shares in the grant?

The filing reports a price of $1.28 per share for the acquired shares.

What is the insider’s relationship to REVB?

The reporting person is a Director of Revelation Biosciences, Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARVER JENNIFER

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								63	D
Common Stock(1)	10/29/2025		A		15,625	A	$1.28	15,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

	/s/ J.P. Galda, as attorney-in-fact for Jennifer Carver	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.